最新公告:

  没有公告

您现在的位置: 心灵之窗-眼科医生网 >> 眼科常识 >> 第17届全国会 >> 正文
专题栏目
更多内容
相关文章
更多内容
Meta-analysis of randomized controlled trials comparing travoprost with latanoprost in the treatment of patients with open angle glaucoma or ocular hypertension           ★★★
Meta-analysis of randomized controlled trials comparing travoprost with latanoprost in the treatment of patients with open angle glaucoma or ocular hypertension
作者:程金伟 文章来源:第二军医大学附属长征医院 点击数:241 更新时间:2012/9/13
Purpose This meta-analysis was to evaluate the efficacy and tolerability of travoprost compared with latanoprost in patients with open angle glaucoma or ocular hypertension.
Methods Pertinent studies were identified through searches of the Cochrane Library, PubMed, EMBASE, and Chinese Biomedicine Database up toJune 1, 2008, using the terms travoprost, Travatan, latanoprost, and Xalatan. Internet searches of meeting abstracts and the manufacturers' databases were also performed. Randomized controlled trials comparing travoprost with latanoprost in patients with open angle glaucoma or ocular hypertension were selected. The main efficacy measures were the weighted mean difference (WMD) in the IOP reduction (IOPR). The main tolerability measure was the relative risk (RR) for adverse events.
Results Seventeen studies enrolling a total of 1491 patients were included in the meta-analysis. The WMDs in the diurnal mean IOPR comparing travoprost with latanoprost were1.47 mmHg (95% confidence interval, 0.33 to 2.62) at 2 weeks, 0.81 (-0.78 to 2.40) at 1 month, 0.71 (0.04 to 1.38) at 2 months, 0.01 (-0.50 to 0.52) at 3 months, and 0.27 (-0.40 to 0.95) at 6 months; significant differences were found at 2 weeks and 2 months. The WMDs in the 17:00 IOPR were0.87 mmHg (0.40 to 1.33) at 2 weeks, 0.60 (0.00 to 1.20) at 1 month, 0.65 (-0.69 to 1.99) at 2 months, 0.04 (-0.51 to 0.59) at 3 months, and 0.30 (-0.36 to 0.96) at 12 months, only the first of which was statistically significant. Travoprost was associated with a significantly greater frequency of hyperemia than latanoprost, with an RR of 1.72 (1.33 to 2.23). Rates of serious ocular adverse events did not differ significantly between travoprost and latanoprost, with an RR of 0.22 (0.03 to 1.76) for cystoid macular edema and 2.29 (0.90 to 5.83) for cataract.
Conclusions Although a significant greater efficacy in the diurnal mean or 17:00 IOP reduction of travoprost than latanoprost was found at 2 weeks. Travoprost and latanoprost was comparable in their ability to reduce IOP. Both agents were well tolerated.
会议投稿录入:毛进    责任编辑:毛进 
  • 上一篇会议投稿:

  • 下一篇会议投稿:
  • 【字体: 】【发表评论】【加入收藏】【告诉好友】【打印此文】【关闭窗口
      网友评论:(只显示最新10条。评论内容只代表网友观点,与本站立场无关!)

    | 设为首页 | 加入收藏 | 联系站长 | 友情链接 | 版权申明 |
    眼科医生网 眼科医生网版权所有 @ 1998-2012
    部分文章和资源来源于网络,如果侵犯了您的版权,请指出! 站长:毛进
    信息产业部备案
    *京ICP备18030162号